Table 2.

Dysregulated miRNAs and their involvement in liver disease. ICC intrahepatic cholangiocarcinoma, HNSCC head and neck squamous cell carcinoma

MicroRNA	Liver disease	Target gene(s)
miR-155	Protective role against non alcoholic steatosis [33]	LXR-α[33] C/EBPβ, FOXP3 [35–37]
	Up-regulated in NASH [34]
	Up-regulated in HCC [35]
	MiR-155 deficiency attenuates steatosis and fibrosis [36]
miR-193b	Down-regulated in HBV+ HCC [43]	CCND1, ETS1 [43]
		NF1 (HNSCC) [46]
		Smad3 (glioma) [47]
miR-20a	Down-regulated in HCC [49]	Mcl-1 [49]
miR-200a	Up-regulated in NAFLD [51]	ZEB1, ZEB2 [54]
miR-200a	Down-regulated in HCC [52]	ZEB1, ZEB2 [54]
miR-200c	Up-regulated in NAFLD [51]	ZEB1, ZEB2, NCAM1 [54]
miR-200c	Down-regulated in HCC and ICC [54]	ZEB1, ZEB2, NCAM1 [54]
miR-27a	Up-regulated in HBV+ HCC [55]	RXRα, PPARα/γ, FASN, SREBP1, SREBP2 [58, 59]
miR-31	Up-regulated in fibrosis [60]	FIH1 [60]
miR-31	Up-regulated in HCC [17, 53]	FIH1 [60]
miR-93	Up-regulated in HCC [61, 62]	PTEN, CDKN1A [62]
miR-99b	Up-regulated in HCC [69]	mTOR (pancreatic cancer) [66]
miR-99b	Up-regulated in HCC [69]	CLDN11 [69]
miR-125a-5p	Down-regulated in HCC [89]	SIRT7 [89]
miR-125a-5p	Biomarker in liver disease [93]	SIRT7 [89]
miR-182	Up-regulated in NAFLD-fibrosis [98]	FOXO3 [98]
	Up-regulated in NAFLD-fibrosis [98]	MTSS1 [94], Cebpa [95],
	Up-regulated in HCC [94–97]	EphrinA5 [96], FOXO1 [97]